Coverage of SY is unusually thin. According to data from S&P Global aggregated by StockAnalysis, only two analysts currently publish 12-month price targets, producing an average near $7.34 with a low near $5.03 and a high near $9.65. Other aggregators report a comparable mean of roughly $7.29, with a low-to-high band around $4.80 to $9.80. Averaging the valid targets and rounding yields the $7.30 central figure used here.
Covering firms include Canaccord Genuity and Citic Securities, while Citi's Nelson Cheung upgraded the stock to Buy in mid-2025 with a target that has since been revised. The gap between the lowest and highest targets is enormous, which signals deep disagreement rather than a confident consensus. Aggregators label the rating anywhere from "Strong Buy" to "Hold," reflecting the split between a turnaround thesis and skepticism about the company's losses. This mean should be read as a rough anchor, not a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
With the stock near $1.97, a rise to $7.30 represents upside of about 270%, which is a very large required move. The 52-week range runs from roughly $1.28 to about $3.90, so even recovering to the prior high would still leave the shares far below the central target.
A path toward the target would require more than a technical bounce. So-Young has been pivoting from its legacy information and reservation services into direct aesthetic treatment centers and equipment sales through its Wuhan Miracle segment. That shift has driven strong segment growth, but it has also compressed gross margins and kept the company loss-making. Consensus estimates point to revenue growth of roughly 35% for fiscal 2026 and continued earnings per share (EPS) losses, meaning the stock would need a substantial re-rating of its valuation multiple, not just top-line improvement.
The 52-week low near $1.28 is the most important downside support level, while the prior highs around $3.90 to $4.75 form the first meaningful resistance zones. The $2.00 mark is a psychological level that the stock has struggled around. A sustained move above $5.00 would be needed to even begin challenging a target near $7.30, and no durable technical structure currently supports that scenario.
Analyst price targets generally reflect a roughly 12-month research horizon, though the two firms covering SY do not publish identical timelines. Investors should watch quarterly earnings and guidance, particularly the growth and profitability of the aesthetic center segment; any analyst target revisions, given how few there are; China's consumer and regulatory environment; and the company's progress toward breakeven. The next earnings report was expected around late November 2026.
In my own analysis process, I find Tickeron's AI Daily Buy/Sell Signals helpful for gaining an extra layer of insight on thinly covered names. The tool applies artificial intelligence to scan market conditions and technical patterns across thousands of stocks, which can complement fundamental work on volatile micro-caps like this one. It has become a regular part of how I cross-check ideas before forming a fuller view.
The $7.30 central target is the mean of just two analyst price targets spanning roughly $4.80 to $9.80, a range so wide that it reflects fundamentally different views of whether So-Young can turn its fast-growing but loss-making clinic and equipment businesses into durable profits. Reaching the target would require a gain of about 270% from current levels, a very large move that depends on accelerating revenue, a return to profitability, and a significant re-rating of the valuation. The strongest supports are the company's growth pivot and its depressed multiple, while the principal obstacles are persistent losses, China's macro and regulatory backdrop, and minimal analyst coverage. Neither the target nor the wide-ranging analyst views should be treated as a forecast, and the outcome remains highly uncertain.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for SY moved out of oversold territory on November 10, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In 41 of the 46 cases the stock moved higher. This puts the odds of a move higher at 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for SY just turned positive on November 06, 2026. Looking at past instances where SY's MACD turned positive, the stock continued to rise in 25 of 38 cases over the following month. The odds of a continued upward trend are 66%.
Following a +6.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where SY advanced for three days, in 221 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
SY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SY as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
SY moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SY crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for SY moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SY entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.523). P/E Ratio (-0.846) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.430) is also within normal values, averaging (1.536). SY has a moderately high Dividend Yield (0.052) as compared to the industry average of (0.011). P/S Ratio (1.067) is also within normal values, averaging (6.105).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. SY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of online information and reservation services related to medical aesthetics
Industry ServicestotheHealthIndustry